AVBP
ArriVent BioPharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$17.94
+7.68%Oct 19, 2026, 12:01 UTC
ArriVent BioPharma, Inc. announced publication in Cell Press of results from the FURTHER Phase 1b study of firmonertinib in EGFR PACC-mutant non-small cell lung cancer.
Source:Oct 8, 2026, 07:49 UTC
Shanghai Allist Pharmaceuticals reported that its ArriVent equity stake had a carrying value of about 302 million yuan as of June 30, 2026, up 67.31% from the end of 2025.
Source:Oct 7, 2026, 08:29 UTC
Shanghai Allist Pharmaceuticals announced that its furmonertinib monotherapy failed to meet the primary endpoint in the FURVENT Phase III trial for first-line treatment of EGFR exon 20 insertion NSCLC.
Source:Oct 6, 2026, 18:09 UTC
ArriVent BioPharma shares fell to a 52-week low on Tuesday, with trading volume of 14.10 million shares versus an average of 524,163.
Source:Oct 6, 2026, 12:00 UTC
ArriVent BioPharma announced that its Phase 3 FURVENT trial of firmonertinib monotherapy in previously untreated EGFR exon 20 insertion mutant non-squamous NSCLC did not meet its primary endpoint of progression-free survival by blinded independent central review.
Aug 12, 2026, 20:01 UTC
ArriVent BioPharma reported its financial results for the second quarter ended June 30, 2026.
Source: